Login / Signup

Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09.

Akihito TsujiMasato NakamuraTakanori WatanabeDai ManakaHiroshi MatsuokaMasato KataokaMasahiro TakeuchiWataru IchikawaMasashi Fujii
Published in: Targeted oncology (2021)
UMIN000015916.
Keyphrases
  • wild type
  • phase ii study
  • locally advanced
  • open label
  • rectal cancer
  • squamous cell carcinoma
  • radiation therapy
  • clinical trial
  • study protocol